Amneal Pharmaceuticals stock sees institutional buying ahead of earnings?? Actually must fix

Published on 10/08/2026 at 04:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amneal Pharmaceuticals stock drew a 94.7 percent institutional holding increase in Q3, while the next report is scheduled for October 29. Q2 EPS reached USD 0.30.

AMRX, US03168L1052, Illustration mit AI erstellt.

Amneal Pharmaceuticals stock (ISIN US03168L1052) is tied to a 94.7 percent increase in Congress Asset Management's AMRX holding during the third quarter of 2026, according to MarketBeat on October 7, 2026. The firm owned 1,524,355 shares after buying 741,577 shares during the quarter.

Institutional ownership rises 94.7 percent

The disclosed position represented 0.48 percent of Amneal Pharmaceuticals and was valued at USD 30.7 million in the cited SEC filing. Institutional investors held 31.82 percent of the company, while the same report said insiders had sold 413,016 shares valued at USD 7.2 million during the previous three months.

The split between institutional buying and insider selling gives the stock a clear counter-factor. The buying disclosure is a quarterly ownership snapshot, while the insider transactions were completed in August and therefore describe an earlier trading period.

Q2 EPS beat consensus by USD 0.06

Amneal's second-quarter 2026 results supplied the latest operating comparison. MarketBeat reported EPS of USD 0.30 versus consensus of USD 0.24 for the quarter ended June 30, 2026, a USD 0.06 difference. Revenue reached USD 796.20 million, and full-year 2026 EPS guidance stood at USD 0.960-1.060.

The next scheduled checkpoint is October 29, 2026, when Amneal is due to report third-quarter results, according to Investing.com. That date puts the institutional ownership disclosure and the latest earnings comparison ahead of the next formal operating update.

Analyst target stays above the stock

The analyst consensus is Moderate Buy from 10 analysts, with nine Buy ratings and one Hold rating and an average target of USD 21.00, according to MarketBeat. The target lies 6.9 percent above the stock's USD 19.65 price on October 7, 2026, leaving the consensus above the latest Nasdaq quotation.

Stock remains below its yearly high

AMRX was last at USD 19.65 on Nasdaq on October 7, 2026 at 4:00 p.m. ET, down 3.18 percent on the session. The USD 19.65 price stood below the 52-week high of USD 21.18 and above the 52-week low of USD 9.56, while market capitalization was USD 6.3 billion and volume was 3,733,558 shares.